Patents by Inventor Hamed Aissaoui

Hamed Aissaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100222600
    Abstract: The invention relates to novel azetidine compounds of formula (I), wherein R1, R2, and X are as described in the description and their use as orexin receptor antagonists.
    Type: Application
    Filed: August 15, 2007
    Publication date: September 2, 2010
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100222328
    Abstract: The invention relates to selected 2-cyclopropyl-thiazole derivatives of the formula (I) wherein B, Y and R1 are as described in the description; to salts and especially pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.
    Type: Application
    Filed: May 13, 2008
    Publication date: September 2, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100204285
    Abstract: The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.
    Type: Application
    Filed: July 25, 2008
    Publication date: August 12, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, David Lehman, Thierry Sifferlen, Daniel Trachsel
  • Publication number: 20100197733
    Abstract: The invention relates to compounds of formula (I) wherein Y, A, N and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to the use of such compounds as medicaments, especially as orexin receptor antagonists.
    Type: Application
    Filed: September 23, 2008
    Publication date: August 5, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Ralf Koberstein, Thierry Sifferlen
  • Patent number: 7763638
    Abstract: The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to a mammal.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: July 27, 2010
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thomas Weller
  • Publication number: 20100184808
    Abstract: The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R1, R2, R3, and A are as described in the description and their use as orexin receptor antagonists.
    Type: Application
    Filed: July 2, 2008
    Publication date: July 22, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100113531
    Abstract: The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.
    Type: Application
    Filed: March 25, 2008
    Publication date: May 6, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100093740
    Abstract: The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    Type: Application
    Filed: December 20, 2007
    Publication date: April 15, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100069418
    Abstract: The invention relates to piperidine compounds of formula (I) wherein X-R1 represents —N(H)-pyrimidinyl, wherein said pyrimidinyl is unsubstituted or mono-substituted wherein the substituent is selected from (C1-4)alkyl or halogen, or X-R1 represents —NH—C(O)-heterocyclyl, wherein the heterocyclyl is selected from benzofuranyl and imidazo[2,1-b]-thiazolyl, wherein said heterocyclyl is unsubstituted or independently mono-, di-, or tri-substituted wherein the substituents are independently selected from (C1-4)alkyl; A represents a phenyl- or thiazolyl-group, wherein the phenyl or thiazolyl is unsubstituted or mono-substituted with (C1-4)alkyl; B represents a phenyl-group, wherein the phenyl is unsubstituted or mono-, or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, cyano and halogen; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagoni
    Type: Application
    Filed: November 29, 2007
    Publication date: March 18, 2010
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100029617
    Abstract: The invention relates to 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives and their use as orexin receptor antagonists.
    Type: Application
    Filed: August 27, 2007
    Publication date: February 4, 2010
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20100016401
    Abstract: The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.
    Type: Application
    Filed: September 28, 2007
    Publication date: January 21, 2010
    Applicant: Actelion Phamaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, David Lehmann, Thierry Sifferlen, Daniel Trachsel
  • Publication number: 20090275588
    Abstract: The invention relates to novel sulfonamide compounds and their use as orexin receptor antagonists.
    Type: Application
    Filed: April 10, 2007
    Publication date: November 5, 2009
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen, Cornella Zumbrunn Acklin
  • Patent number: 7538109
    Abstract: The invention relates to quinoxalinone derivatives of general Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: May 26, 2009
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Hamed Aissaoui, Martine Clozel, Thomas Weller, Ralf Koberstein, Thierry Sifferlen
  • Publication number: 20090099228
    Abstract: The invention relates to novel pyrazolo-tetrahydropyridines compounds and their use as orexin receptor antagonists.
    Type: Application
    Filed: April 25, 2007
    Publication date: April 16, 2009
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
  • Patent number: 7435815
    Abstract: The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: October 14, 2008
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thierry Sifferlen, Thomas Weller
  • Patent number: 7375227
    Abstract: The invention relates to novel 1-pyridin-4-yl urea derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: May 20, 2008
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Binkert, Martine Clozel, Boris Mathys, Claus Mueller, Oliver Nayler, Michael Scherz, Jörg Velker, Thomas Weller
  • Publication number: 20070244156
    Abstract: The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    Type: Application
    Filed: May 31, 2007
    Publication date: October 18, 2007
    Applicant: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thierry Sifferlen, Thomas Weller
  • Patent number: 7279578
    Abstract: The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: October 9, 2007
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thierry Sifferlen, Thomas Weller
  • Publication number: 20070191424
    Abstract: The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, phannaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to a mammal.
    Type: Application
    Filed: February 23, 2005
    Publication date: August 16, 2007
    Inventors: Hamed Aissaoui, Martine Clozel, Walter Fischli, Ralf Koberstein, Thomas Weller
  • Patent number: 7192950
    Abstract: The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 20, 2007
    Assignee: Actelion Pharmaceuticals, Ltd.
    Inventors: Hamed Aissaoui, Martine Clozel, Thomas Weller, Ralf Koberstein, Thierry Sifferlen, Walter Fischli